Lox-1 and its splice variants: A new challenge for atherosclerosis and cancer-targeted therapies

International Journal of Molecular Sciences

Volumn 18, Issue 2, 2017, Pages

  Rizzacasa, Barbara ^a   Morini, Elena ^a   Pucci, Sabina ^a   Murdocca, Michela ^a   Novelli, Giuseppe ^a   Amati, Francesca ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alternative splicing; Atherosclerosis; Cancer; OLR1

Indexed keywords

AMILORIDE; INSULIN RECEPTOR; MYOTONIC DYSTROPHY PROTEIN KINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PYRUVATE KINASE; SMALL NUCLEAR RIBONUCLEOPROTEIN; ZINC FINGER PROTEIN; ISOPROTEIN; MESSENGER RNA; OLR1 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1;

ALTERNATIVE RNA SPLICING; AORTA STENOSIS; ATHEROSCLEROSIS; CARCINOGENESIS; CELL PROLIFERATION; ELECTROCARDIOGRAPHY; GENE; GENETIC DISORDER; HUMAN; INTRON RETENTION; MOUSE; NONHUMAN; OLR1 GENE; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SPINAL MUSCULAR ATROPHY; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; RNA SPLICING; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; ANIMALS; ATHEROSCLEROSIS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ISOFORMS; RNA SPLICING; RNA, MESSENGER; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION;

EID: 85011105088     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18020290     Document Type: Review

References (226)

1. Licatalosi, D.D.; Darnell, R.B. RNA processing and its regulation: Global insights into biological networks. Nat. Rev. Genet. 2010, 11, 75–87.
2. Tazi, J.; Bakkour, N; Stamm, S Alternative splicing and disease. Biochim. Biophys. Acta 2009, 1792, 14–26.
3. Wang, G.S.; Cooper, T.A. Splicing in disease: Disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 2007, 8, 749–761.
4. Venables, J.P. Aberrant and alternative splicing in cancer. Cancer Res. 2004, 64, 7647–7654.
5. Scherrer, K.; Latham, H.; Darnell, J.E. Demonstration of an unstable RNA and of a precursor to ribosomal RNA in HeLa cells. Proc. Natl. Acad. Sci. USA 1963, 49, 240–248.
6. Soeiro, R.; Vaughan, M.H; Warner, J.R.; Darnell, J.E. The turnover of nuclear DNA-like RNA in HeLa cells. J. Cell Biol. 1968, 39, 112–118.
7. Sahebi, M.; Hanafi, M.M.; van Wijnen, A.J.; Azizi, P.; Abiri, R.; Ashkani, S.; Taheri, S. Towards understanding pre-mRNA splicing mechanisms and the role of SR proteins. Gene 2016, 587, 107–119, doi:10.1016/j.gene.2016.04.057.
8. Pandya-Jones, A.; Black, D.L. Co-transcriptional splicing of constitutive and alternative exons. RNA 2009, 15, 1896–1908, doi:10.1261/rna.1714509.
9. Ameur, A.; Zaghlool, A.; Halvardson, J.; Wetterbom, A.; Gyllensten, U.; Cavelier, L.; Feuk, L. Total RNA sequencing reveals nascent transcription and widespread co-transcriptional splicing in the human brain. Nat. Struct. Mol. Biol. 2011, 18, 1435–1440.
10. Tilgner, H.; Knowles, D.G.; Johnson, R.; Davis, C.A.; Chakrabortty, S.; Djebali, S.; Curado, J.; Snyder, M.; Gingeras, T.R.; Guigó, R. Deep sequencing of subcellular RNA fractions shows splicing to be predominantly co-transcriptional in the human genome but inefficient for lncRNAs. Genome Res. 2012, 22, 1616–1625.
11. Kornblihtt, A.R.; Schor, I.E.; Alló, M.; Dujardin, G.; Petrillo, E.; Muñoz, M.J. Alternative splicing: A pivotal step between eukaryotic transcription and translation. Nat. Rev. Mol. Cell Biol. 2013, 14, 153–165.
12. Kadener, S.; Fededa, J.P.; Rosbash, M.; Kornblihtt, A.R. Regulation of alternative splicing by a transcriptional enhancer through RNA pol II elongation. Proc. Natl. Acad. Sci. USA 2002, 99, 8185–8190.
13. Nogués, G.; Kadener, S.; Cramer, P.; Bentley, D.; Kornblihtt, A.R. Transcriptional activators differ in their abilities to control alternative splicing. J. Biol. Chem. 2002, 277, 43110–43114.
14. Auboeuf, D.; Dowhan, D.H.; Li, X.; Larkin, K.; Ko, L.; Berget, S.M.; O’Malley, B.W. CoAA, a nuclear receptor coactivator protein at the interface of transcriptional coactivation and RNA splicing. Mol. Cell. Biol. 2004, 24, 442–453.
15. Batsché, E.; Yaniv, M.; Muchardt, C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat. Struct. Mol. Biol. 2006, 13, 22–29.
16. Schor, I.E.; Rascovan, N.; Pelisch, F.; Alló, M.; Kornblihtt, A.R. Neuronal cell depolarization induces intragenic chromatin modifications affecting NCAM alternative splicing. Proc. Natl. Acad. Sci. USA 2009, 106, 4325–4330.
17. Luco, R.F.; Pan, Q.; Tominaga, K.; Blencowe, B.J.; Pereira-Smith, O.M.; Misteli, T. Regulation of alternative splicing by histone modifications. Science 2010, 327, 996–1000.
18. Saint-André, V.; Batsché, E.; Rachez, C.; Muchardt, C. Histone H3 lysine 9 trimethylation and HP1γ favor inclusion of alternative exons. Nat. Struct. Mol. Biol. 2011, 18, 337–344.
19. Matlin, A.J.; Clark, F.; Smith, C.W. Understanding alternative splicing: Towards a cellular code. Nat. Rev. Mol. Cell Biol. 2005, 6, 386–398.
20. Manley, J.L.; Tacke, R. SR proteins and splicing control. Genes Dev. 1996, 10, 1569–1579.
21. Graveley, B.R. Sorting out the complexity of SR protein functions. RNA 2000, 6, 1197–1211.
22. Shen, H.; Green, M.R. RS domains contact splicing signals and promote splicing by a common mechanism in yeast through humans. Genes Dev. 2006, 20, 1755–1765.
23. Maatz, H.; Jens, M.; Liss, M.; Schafer, S.; Heinig, M.; Kirchner, M.; Adami, E.; Rintisch, C.; Dauksaite, V.; Radke, M.H.; et al. RNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J. Clin. Investig. 2014, 124, 3419–3430.
24. Yang, J.; Hung, L.H.; Licht, T.; Kostin, S.; Looso, M.; Khrameeva, E.; Bindereif, A.; Schneider, A.; Braun, T. RBM24 is a major regulator of muscle-specific alternative splicing. Dev. Cell 2014, 31, 87–99.
25. Kanopka, A.; Mühlemann, O.; Akusjärvi, G. Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA. Nature 1996, 381, 535–538.
26. Giudice, J.; Cooper, T.A. RNA-binding proteins in heart development. Adv. Exp. Med. Biol. 2014, 825, 389–429.
27. Black, D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 2003, 72, 291–336.
28. Wahl, M.C.; Will, C.L.; Lührmann, R. The spliceosome: Design principles of a dynamic RNP machine. Cell 2009, 136, 701–718.
29. Berglund, J.A.; Chua, K.; Abovich, N.; Reed, R.; Rosbash, M. The splicing factor BBP interacts specifically with the pre-mRNA branchpoint sequence UACUAAC. Cell 1997, 89, 781–787.
30. Kent, O.A.; Ritchie, D.B.; Macmillan, A.M. Characterization of a U2AF-independent commitment complex (E’) in the mammalian spliceosome assembly pathway. Mol. Cell. Biol. 2005, 25, 233–240.
31. Chen, M.; Manley, J.L. Mechanisms of alternative splicing regulation: Insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 2009, 10, 741–754.
32. Shen, H.; Kan, J.L. Arginine-serine-rich domains bound at splicing enhancers contact the branchpoint to promote prespliceosome assembly. Mol. Cell 2004, 13, 367–376.
33. Kohtz, J.D.; Jamison, S.F.; Will, C.L.; Zuo, P.; Lührmann, R.; Garcia-Blanco, M.A.; Manley, J.L. Protein-protein interactions and 5’-splice-site recognition in mammalian mRNA precursors. Nature 1994, 368, 119–124.
34. Wu, J.Y.; Maniatis, T. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell 1993, 75, 1061–1070.
35. Longman, D.; McGarvey, T.; McCracken, S.; Johnstone, I.L.; Blencowe, B.J.; Cáceres, J.F. Multiple interactions between SRm160 and SR family proteins in enhancer-dependent splicing and development of C. elegans. Curr. Biol. 2001, 11, 1923–1933.
36. Blencowe, B.J.; Baurén, G.; Eldridge, A.G.; Issner, R.; Nickerson, J.A.; Rosonina, E.; Sharp, P.A. The SRm160/300 splicing coactivator subunits. RNA 2000, 6, 111–120.
37. Tacke, R.; Manley, J.L. Functions of SR and Tra2 proteins in pre-mRNA splicing regulation. Proc. Soc. Exp. Biol. Med. 1999, 220, 59–63.
38. Modrek, B.; Lee, C. A genomic view of alternative splicing. Nat. Genet. 2002, 30, 13–19.
39. Pan, Q.; Shai, O.; Lee, L.J.; Frey, BJ.; Blencowe, B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40, 1413–1415.
40. Wang, E.T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S.F.; Schroth, G.P.; Burge, C.B. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456, 470–476.
41. Blencowe, B.J. Alternative splicing: New insights from global analyses. Cell 2006, 126, 37–47.
42. Alekseyenko, A.V.; Kim, N.; Lee, C.J. Global analysis of exon creation versus loss and the role of alternative splicing in 17 vertebrate genomes. RNA 2007, 13, 661–670.
43. Sugnet, C.W.; Kent, W.J.; Ares, M.; Haussler, D. Transcriptome and genome conservation of alternative splicing events in humans and mice. Pac. Symp. Biocomput. 2004, 9, 66–77.
44. Keren, H.; Lev-Maor, G.; Ast, G. Alternative splicing and evolution: Diversification, exon definition and function. Nat. Rev. Genet. 2010, 11, 345–355.
45. Ohler, U.; Shomron, N.; Burge, C.B. Recognition of unknown conserved alternatively spliced exons. PLoS Comput. Biol. 2005, 1, 113–122.
46. Kim, E.; Goren, A.; Ast, G. Alternative splicing: Current perspectives. Bioessays 2008, 30, 38–47.
47. Sakabe, N.J.; de Souza, S.J. Sequence features responsible for intron retention in human. BMC Genom. 2007, 8, 59, doi:10.1186/1471-2164-8-59.
48. Ast, G. How did alternative splicing evolve? Nat. Rev. Genet. 2004, 5, 773–782.
49. Cooper, T.A.; Wan, L.; Dreyfuss, G. RNA and disease. Cell 2009, 136, 777–793.
50. Ward, A.J.; Cooper, T.A. The pathobiology of splicing. J. Pathol. 2010, 220, 152–163.
51. Krawczak, M.; Thomas, N.S.; Hundrieser, B.; Mort, M.; Wittig, M.; Hampe, J.; Cooper, D.N. Single base-pair substitutions in exon-intron junctions of human genes: Nature, distribution, and consequences for mRNA splicing. Hum. Mutat. 2007, 28, 150–158.
52. Sterne-Weiler, T.; Howard, J.; Mort, M.; Cooper, D.N.; Sanford, J.R. Loss of exon identity is a common mechanism of human inherited disease. Genome Res. 2011, 21, 1563–1571.
53. Singh, R.K.; Cooper, T.A. Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 2012, 18, 472–482.
54. Takeshima, Y.; Yagi, M.; Okizuka, Y.; Awano, H.; Zhang, Z.; Yamauchi, Y.; Nishio, H.; Matsuo, M. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. J. Hum. Genet. 2010, 55, 379–388.
55. Fletcher, S.; Meloni, P.L.; Johnsen, R.; Wong, B.L.; Muntoni, F.; Wilton, S.D. Antisense suppression of donor splice site mutations in the dystrophin gene transcript. Mol. Genet. Genom. Med. 2013, 1, 162–173.
56. Harper, P.S. Major Problems in Neurology: Myotonic. Dystrophy; 3rd ed.; WB Saunders Harcourt Publishers Ltd.: London, UK, 2001.
57. Brook, J.D.; McCurrach, M.E.; Harley, H.G.; Buckler, A.J.; Church, D.; Aburatani, H.; Hunter, K. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 30 end of a transcript encoding a protein kinase family member. Cell 1992, 68, 799–808.
58. Caskey, C.T.; Swanson, M.S.; Timchenko, L.T. Myotonic dystrophy: Discussion of molecular mechanism. Cold Spring Harbor Symp. Quant. Biol. 1996, 61, 607–614.
59. Lin, S.L.; Ying, S.Y. Gene silencing in vitro and in vivo using intronic microRNAs. Methods Mol. Biol. 2006, 342, 295–312.
60. Kalsotra, A.; Xiao, X. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc. Natl. Acad. Sci. USA 2008, 105, 20333–20338.
61. Chau, A.; Kalsotra, A. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics. Dev. Dyn. 2015, 244, 377–390.
62. Osborne, R.J.; Thornton, C.A. RNA-dominant diseases. Hum. Mol. Genet. 2006, doi:10.1093/hmg/ddl181.
63. Liquori, C.L.; Ricker, K.; Moseley, M.L.; Jacobsen, J.F.; Kress, W.; Naylor, S.L.; Day, J.W.; Ranum, L.P. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001, 293, 864–867.
64. Botta, A.; Vallo, L.; Rinaldi, F.; Bonifazi, E.; Amati, F.; Biancolella, M.; Gambardella, S.; Mancinelli, E.; Angelini, C.; Meola, G.; et al. Gene expression analysis in myotonic dystrophy: Indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr. 2007, 13, 339–351.
65. Scotti, M.M.; Swanson, M.S. RNA mis-splicing in disease. Nat. Rev. Genet. 2016, 17, 19–32.
66. D’Amico, A.; Mercuri, E.; Tiziano, F.D.; Bertini, E. Spinal muscular atrophy. Orphanet J. Rare Dis. 2011, 6, 71, doi:10.1186/1750-1172-6-71.
67. Lefebvre, S.; Bürglen, L.; Reboullet, S.; Clermont, O.; Burlet, P.; Viollet, L.; Benichou, B.; Cruaud, C.; Millasseau, P.; Zeviani, M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80, 155–165.
68. Lorson, C.L.; Hahnen, E.; Androphy, E.J.; Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. USA 1999, 96, 6307–6311.
69. Monani, U.R.; Lorson, C.L.; Parsons, D.W.; Prior, T.W.; Androphy, E.J.; Burghes, A.H.; McPherson, J.D. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8, 1177–1183.
70. Ahmad, S.; Bhatia, K.; Kannan, A.; Gangwani, L. Molecular mechanisms of neurodegeneration in spinal muscular atrophy. J. Exp. Neurosci. 2016, 10, 39–49.
71. Fischer, U.; Englbrecht, C.; Chari, A. Biogenesis of spliceosomal small nuclear ribonucleoproteins. Wiley Interdiscip. Rev. RNA 2011, 2, 718–731, doi:10.1002/wrna.87.
72. Fischer, U.; Liu, Q.; Dreyfuss, G. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 1997, 90, 1023–1029.
73. Meister, G.; Bühler, D.; Pillai, R.; Lottspeich, F.; Fischer, U. A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs. Nat. Cell Biol. 2001, 3, 945–949.
74. Pellizzoni, L.; Yong, J.; Dreyfuss, G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 2002, 298, 1775–1779.
75. Chari, A.; Golas, M.M.; Klingenhäger, M.; Neuenkirchen, N.; Sander, B.; Englbrecht, C.; Sickmann, A.; Stark, H.; Fischer, U. An assembly chaperone collaborates with the SMN complex to generate spliceosomal SnRNPs. Cell 2008, 135, 497–509.
76. Ghigna, C.; Valacca, C.; Biamonti, G. Alternative splicing and tumor progression. Curr. Genom. 2008, 9, 556–570.
77. David, C.J.; Manley, J.L. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev. 2010, 24, 2343–2364.
78. Biamonti, G.; Bonomi, S.; Gallo, S.; Ghigna, C. Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT). Cell. Mol. Life Sci. 2012, 69, 2515–2526.
79. He, C.; Zhou, F.; Zuo, Z.; Cheng, H.; Zhou, R. A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS ONE 2009, 4, e4732.
80. Britton, C.H.; Schultz, R.A.; Zhang, B.; Esser, V.; Foster, D.W.; McGarry, J.D. Human liver mitochondrial carnitine palmitoyltransferase I: Characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc. Natl. Acad. Sci. USA 1995, 92, 1984–1988.
81. Weis, B.C.; Cowan, A.T.; Brown, N.; Foster, D.W.; McGarry, J.D. Use of a selective inhibitor of liver carnitine palmitoyltransferase I (CPT I) allows quantification of its contribution to total CPT I activity in rat heart. Evidence that the dominant cardiac CPT I isoform is identical to the skeletal muscle enzyme. J. Biol. Chem. 1994, 269, 26443–26448.
82. Pucci, S.; Zonetti, M.J.; Fisco, T.; Polidoro, C.; Bocchinfuso, G.; Palleschi, A.; Novelli, G.; Spagnoli, L.G.; Mazzarelli, P. Carnitine palmitoyl transferase-1A (CPT1A): A new tumor specific target in human breast cancer. Oncotarget 2016, 7, 19982–19996.
83. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
84. Okumura, N.; Yoshida, H.; Kitagishi, Y.; Nishimura, Y.; Matsuda, S. Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem. Biophys. Res. Commun. 2011, 413, 395–399.
85. Cohen, J.B.; Broz, S.D.; Levinson, A.D. Expression of the H-ras proto-oncogene is controlled by alternative splicing. Cell 1989, 58, 461–72.
86. Reiter, J.; Maihle, N.J. Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann. N. Y. Acad. Sci. 2003, 995, 39–47.
87. Marcel, V.; Dichtel-Danjoy, M.L.; Sagne, C.; Hafsi, H.; Ma, D.; Ortiz-Cuaran, S.; Olivier, M.; Hall, J.; Mollereau, B.; Hainaut, P.; Bourdon, J.C. Biological functions of p53 isoforms through evolution: Lessons from animal and cellular models. Cell Death Differ. 2011, 18, 1815–1824.
88. Reiter, J.L.; Threadgill, D.W.; Eley, G.D.; Strunk, K.E.; Danielsen, A.J.; Sinclair, C.S.; Pearsall, R.S.; Green, P.J.; Yee, D.; Lampland, A.L.; et al. Comparative genomic sequence analysis and isolation of human and mouse alternative EGFR transcripts encoding truncated receptor isoforms. Genomics 2001, 71, 1–20.
89. Witsch, E.; Sela, M.; Yarden, Y. Roles for growth factors in cancer progression. Physiology 2010, 25, 85–101.
90. Perona, R. Cell signalling: Growth factors and tyrosine kinase receptors. Clin. Transl. Oncol. 2006, 8, 77–82.
91. Hynes, N.E.; MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell. Biol. 2009, 21, 177–184.
92. Giudice, J.; Xia, Z.; Wang, E.T.; Scavuzzo, M.A.; Ward, A.J.; Kalsotra, A.; Wang, W.; Wehrens, X.H.; Burge C.B.; Li, W.; et al. Alternative splicing regulates vesicular trafficking genes in cardiomyocytes during postnatal heart development. Nat. Commun. 2014, 5, 3603, doi:10.1038/ncomms4603.
93. Manley, J.L.; Krainer, A.R. A rational nomenclature for serine/arginine-rich protein splicing factors (SR proteins). Genes Dev. 2010, 24, 1073–1074.
94. Xu, X.; Yang, D.; Ding, J.H.; Wang, W.; Chu, P.H.; Dalton, N.D.; Wang, H.Y.; Bermingham, J.R.; Ye, Z.; Liu, F.; et al. ASF/SF2-regulated CaMKIIdelta alternative splicing temporally reprograms excitation-contraction coupling in cardiac muscle. Cell 2005, 120, 59–72.
95. Van den Hoogenhof, M.M.; Pinto, Y.M.; Creemers, E.E. RNA Splicing: Regulation and Dysregulation in the Heart. Circ. Res. 2016, 118, 454–468.
96. Ding, J.H.; Xu, X.; Yang, D.; Chu, P.H.; Dalton, N.D.; Ye, Z.; Yeakley, J.M.; Cheng, H.; Xiao, R.P.; Ross, J.; et al. Dilated cardiomyopathy caused by tissue-specific ablation of SC35 in the heart. EMBO J. 2004, 23, 885–896.
97. Lanner, J.T.; Georgiou, D.K.; Joshi, A.D.; Hamilton, S.L. Ryanodine receptors: Structure, expression, molecular details, and function in calcium release. Cold Spring Harb. Perspect. Biol. 2010, 2, a003996, doi:10.1101/cshperspect.a003996.
98. Taegtmeyer, H.; Sen, S.; Vela, D. Return to the fetal gene program: A suggested metabolic link to gene expression in the heart. Ann. N. Y. Acad. Sci. 2010, 1188, 191–198.
99. Ames, E.G.; Lawson, M.J.; Mackey, A.J.; Holmes, J.W. Sequencing of mRNA identifies re-expression of fetal splice variants in cardiac hypertrophy. J. Mol. Cell. Cardiol. 2013, 62, 99–107.
100. Weeland, C.J.; van den Hoogenhof, M.M.; Beqqali, A.; Creemers, E.E. Insights into alternative splicing of sarcomeric genes in the heart. J. Mol. Cell. Cardiol. 2015, 81, 107–113.
101. Kong, S.W.; Hu, Y.W.; Ho, J.W.; Ikeda, S.; Polster, S.; John, R.; Hall, J.L.; Bisping, E.; Pieske, B.; dos Remedios, C.G.; et al. Heart failure-associated changes in RNA splicing of sarcomere genes. Circ. Cardiovasc. Genet. 2010, 3, 138–146.
102. Thierfelder, L.; Watkins, H.; MacRae, C.; Lamas, R.; McKenna, W.; Vosberg, H.P.; Seidman, J.G.; Seidman, C.E. α-Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: A disease of the sarcomere. Cell 1994, 77, 701–712.
103. Hong, K.; Guerchicoff, A.; Pollevick, G.D.; Oliva, A.; Dumaine, R.; de Zutter, M.; Burashnikov, E.; Wu, Y.S.; Brugada, J.; Brugada, P.; et al. Cryptic 5’ splice site activation in SCN5A associated with Brugada syndrome. J. Mol. Cell. Cardiol. 2005, 38, 555–560.
104. Wang, J.; Zhang, J.; Li, K.; Zhao, W.; Cui, Q. SpliceDisease database: Linking RNA splicing and disease. Nucleic Acids Res. 2012, 40, D1055–D1059.
105. Oltean, S. Modulators of alternative splicing as novel therapeutics in cancer. World J. Clin. Oncol. 2015, 6, 92–95.
106. Bonetta, L. RNA-based therapeutics: Ready for delivery? Cell 2009, 136, 581–584.
107. Havens, M.A.; Hastings, M.L. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016, 44, 6549–6563.
108. Passini, M.A.; Bu, J.; Richards, A.M.; Kinnecom, C.; Sardi, S.P.; Stanek, L.M.; Hua, Y.; Rigo, F.; Matson, J.; Hung, G.; et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 2011, 3, 72ra18, doi:10.1126/scitranslmed.3001777.
109. Karkare, S.; Bhatnagar, D. Promising nucleic acid analogs and mimics: Characteristic features and applications of PNA, LNA, and morpholino. Appl. Microbiol. Biotechnol. 2006, 71, 575–586.
110. Hua, Y.; Sahashi, K.; Rigo, F.; Hung, G.; Horev, G.; Bennett, C.F.; Krainer, A.R. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478, 123–126.
111. Ek, C.J.; Habgood, M.D.; Dziegielewska, K.M.; Saunders, N.R. Structural characteristics and barrier properties of the choroid plexuses in developing brain of the opossum (Monodelphis domestica). J. Comp. Neurol. 2003, 460, 451–464.
112. Kanadia, R.N.; Shin, J.; Yuan, Y.; Beattie, S.G.; Wheeler, T.M.; Thornton, C.A.; Swanson, M.S. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc. Natl. Acad. Sci. USA 2006, 103, 11748–11753.
113. Chamberlain, C.M.; Ranum, L.P. Mouse model of muscleblind-like 1 overexpression: Skeletal muscle effects and therapeutic promise. Hum. Mol. Genet. 2012, 21, 4645–4654.
114. Furling, D.; Lam le, T.; Agbulut, O.; Butler-Browne, G.S.; Morris, G.E. Changes in myotonic dystrophy protein kinase levels and muscle development in congenital myotonic dystrophy. Am. J. Pathol. 2003, 162, 1001–1009.
115. Mulders, S.A.; van den Broek, W.J.; Wheeler, T.M.; Croes, H.J.; van Kuik-Romeijn, P.; de Kimpe, S.J.; Furling, D.; Platenburg, G.J.; Gourdon, G.; Thornton, C.A.; et al. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc. Natl. Acad. Sci. USA 2009, 106, 13915–13920.
116. Wheeler, T.M.; Sobczak, K.; Lueck, J.D.; Osborne, R.J.; Lin, X.; Dirksen, R.T.; Thornton, C.A. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009, 325, 336–339.
117. Warf, M.B.; Diegel, J.V.; von Hippel, P.H.; Berglund, J.A. The protein factors MBNL1 and U2AF65 bind alternative RNA structures to regulate splicing. Proc. Natl. Acad. Sci. USA 2009, 106, 9203–9208.
118. Ding, Y.; Zhang, H.; Zhang, H.; Zhou, Z.; Zhong, M.; Chen, Q., Wang, X.; Zhu, Z. u-PA inhibitor amiloride suppresses peritoneal metastasis in gastric cancer. World J. Surg. Oncol. 2012, 10, 270, doi:10.1186/1477-7819-10-270.
119. Fukuhara, T.; Hosoya, T.; Shimizu, S.; Sumi, K.; Oshiro, T.; Yoshinaka, Y.; Suzuki, M.; Yamamoto, N.; Herzenberg, L.A.; Herzenberg, L.A.; et al. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. Proc. Natl. Acad. Sci. USA 2006, 103, 11329–11333.
120. Gammons, M.V.; Fedorov, O.; Ivison, D.; Du, C.; Clark, T.; Hopkins, C.; Hagiwara, M.; Dick, A.D.; Cox, R.; Harper, S.J.; et al. Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Investig. Ophthalmol. Vis. Sci. 2013, 54, 6052–6062.
121. Gammons, M.V.; Lucas, R.; Dean, R.; Coupland, S.E.; Oltean, S.; Bates, D.O. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br. J. Cancer 2014, 111, 477–485.
122. Mavrou, A.; Brakspear, K.; Hamdollah-Zadeh, M.; Damodaran, G.; Babaei-Jadidi, R.; Oxley, J.; Gillatt, D.A.; Ladomery, M.R.; Harper, S.J.; Bates, D.O.; et al. Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 2015, 34, 4311–4319.
123. Naryshkin, N.A.; Weetall, M.; Dakka, A.; Narasimhan, J.; Zhao, X.; Feng, Z.; Ling, K.K.; Karp, G.M.; Qi, H.; Woll, M.G.; et al. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 2014, 345, 688–693.
124. Sawamura, T.; Kume, N.; Aoyama, T.; Moriwaki, H.; Hoshikawa, H.; Aiba, Y.; Tanaka, T.; Miwa, S.; Katsura, Y.; Kita, T.; et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997, 386, 73–77.
125. Aoyama, T.; Chen, M.; Fujiwara, H.; Masaki, T.; Sawamura, T. LOX-1 mediates lysophosphatidylcholineinduced oxidized LDL uptake in smooth muscle cells. FEBS Lett. 2000, 467, 217–220.
126. Chen, M.; Masaki, T.; Sawamura, T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: Implications in endothelial dysfunction and atherosclerosis. Pharmacol. Ther. 2002, 95, 89–100.
127. Yoshida, H.; Kondratenko, N.; Green, S.; Steinberg, D.; Quehenberger, O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem. J. 1998, 334, 9–13.
128. Joo, H.; Li, D.; Kim, T.W.; Duluc, D.; Upchurch, K.; Xue, Y.; Zurawski, S.; Le Grand, R.; Liu, Y.J.; Kuroda, M.; et al. C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity 2014, 41, 592–604.
129. Yamanaka, S.; Zhang, X.Y.; Miura, K.; Kim, S.; Iwao, H. The human gene encoding the lectin-type oxidized LDL receptor (OLR1) is a novel member of the natural killer gene complex with a unique expression profile. Genomics 1998, 54, 191–199.
130. Jono, T.; Miyazaki, A.; Nagai, R.; Sawamura, T.; Kitamura, T.; Horiuchi, S. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE). FEBS Lett. 2002, 511, 170–174.
131. Shimaoka, T.; Kume, N.; Minami, M.; Hayashida, K.; Sawamura, T.; Kita, T.; Yonehara, S. LOX-1 supports adhesion of Gram-positive and Gram-negative bacteria. J. Immunol. 2001, 166, 5108–5114.
132. Ohki, I.; Ishigaki, T.; Oyama, T.; Matsunaga, S.; Xie, Q.; Ohnishi-Kameyama, M.; Murata, T.; Tsuchiya, D.; Machida, S.; Morikawa, K.; et al. Crystal structure of human lectin-like, oxidized low-density lipoprotein receptor 1 ligand binding domain and its ligand recognition mode to OxLDL. Structure 2005, 13, 905–917.
133. Xie, Q.; Matsunaga, S.; Niimi, S.; Ogawa, S.; Tokuyasu, K.; Sakakibara, Y.; Machida, S. Human lectin-like oxidized low-density lipoprotein receptor-1 functions as a dimer in living cells. DNA Cell Biol. 2004, 23, 111–117.
134. Francone, O.L.; Tu, M.; Royer, L.J.; Zhu, J.; Stevens, K.; Oleynek, J.J.; Lin, Z.; Shelley, L.; Sand, T.; Luo, Y.; et al. The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding. J. Lipid Res. 2009, 50, 546–555.
135. Murphy, J.E.; Vohra, R.S.; Dunn, S; Holloway, Z.G., Monaco, A.P.; Homer-Vanniasinkam, S.; Walker, J.H.; Ponnambalam, S. Oxidised LDL internalisation by the LOX-1 scavenger receptor is dependent on a novel cytoplasmic motif and is regulated by dynamin-2. J. Cell Sci. 2008, 121, 2136–2147.
136. Vohra, R.S.; Walker, J.H.; Howell, G.J.; Homer-Vanniasinkam, S.; Ponnambalam, S. The LOX-1 scavenger receptor cytoplasmic domain contains a transplantable endocytic motif. Biochem. Biophys. Res. Commun. 2009, 383, 269–274.
137. Kumano-Kuramochi, M.; Xie, Q.; Kajiwara, S.; Komba, S.; Minowa, T.; Machida, S. Lectin-like oxidized LDL receptor-1 is palmitoylated and internalizes ligands via caveolae/raft-dependent endocytosis. Biochem. Biophys. Res. Commun. 2013, 434, 594–599.
138. Aoyama, T.; Sawamura, T.; Furutani, Y.; Matsuoka, R.; Yoshida, M.C.; Fujiwara, H.; Masaki, T. Structure and chromosomal assignment of the human lectin-like oxidized low-density-lipoprotein receptor-1 (LOX-1) gene. Biochem. J. 1999, 339, 177–184.
139. Chen, J.; Liu, Y.; Liu, H.; Hermonat, P.L.; Mehta, J.L. Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1163–1168.
140. Hermonat, P.L.; Zhu, H.; Cao, M.; Mehta, J.L. LOX-1 transcription. Cardiovasc. Drugs Ther. 2011, 25, 393–400.
141. Chen, M.; Narumiya, S.; Masaki, T.; Sawamura, T. Conserved C-terminal residues within the lectin-like domain of LOX-1 are essential for oxidized low-density-lipoprotein binding. Biochem. J. 2001, 355, 289–296.
142. Biocca, S.; Filesi, I.; Mango, R.; Maggiore, L.; Baldini, F.; Vecchione, L.; Viola, A., Citro, G.; Federici, G.; Romeo, F.; et al. The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. J. Mol. Cell. Cardiol. 2008, 44, 61–70.
143. Veas, C.; Jara, C.; Willis, N.D.; Pérez-Contreras, K.; Gutierrez, N.; Toledo, J.; Fernandez, P.; Radojkovic, C.; Zuñiga, F.A.; Escudero, C.; et al. Overexpression of LOXIN Protects Endothelial Progenitor Cells From Apoptosis Induced by Oxidized Low Density Lipoprotein. J. Cardiovasc. Pharmacol. 2016, 67, 326–335.
144. Moriwaki, H.; Kume, N. Sawamura, T.; Aoyama, T.; Hoshikawa, H.; Ochi, H., Nishi, E.; Masaki, T.; Kita, T. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 1998, 18, 1541–1547.
145. Vural, P.; Akgül, C.; Yildirim, A.; Canbaz, M. Antioxidant defence in recurrent abortion. Clin. Chim. Acta 2000, 295, 169–177.
146. Gupta, S.; Agarwal, A.; Banerjee, J.; Alvarez, J.G. The role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: A systematic review. Obstet. Gynecol. Surv. 2007, 62, 335–347.
147. Bruno, V.; Rizzacasa, B.; Pietropolli, A.; Capogna, M.V.; Massoud, R.; Ticconi, C.; Piccione, E.; Cortese, C., Novelli, G.; Amati, F. OLR1 and Loxin expression in PBMCs of women with a history of unexplained recurrent miscarriage: A pilot study. Genet. Test. Mol. Biomark. 2017, in press.
148. Vecchione, L.; Diano, L.; Campagnolo, L.; Rocchi, L.; Ferrè, F.; Mehta, J.L.; Novelli, G.; Amati, F. Functional characterization and expression analysis of novel alternative splicing isoforms of Olr1 gene during mouse embryogenesis. Gene 2012, 491, 5–12.
149. Kuiper, R.P.; Schepens, M.; Thijssen, J.; Schoenmakers, E.F.; van Kessel, A.G. Regulation of the MiTF/TFE bHLH-LZ transcription factors through restricted spatial expression and alternative splicing of functional domains. Nucleic Acids Res. 2004, 32, 2315–2322.
150. Marden, J.H. Quantitative and evolutionary biology of alternative splicing: How changing the mix of alternative transcripts affects phenotypic plasticity and reaction norms. Heredity 2008, 100, 111–120.
151. Nissim-Rafinia, M.; Kerem, B. Splicing regulation as a potential genetic modifier. Trends Genet. 2002, 18, 123–127.
152. Královicová, J.; Houngninou-Molango, S.; Krämer, A.; Vorechovsky, I. Branch site haplotypes that control alternative splicing. Hum. Mol. Genet. 2004, 13, 3189–3202.
153. Chen, Q.; Reis, S.E.; Kammerer, C.; Craig, W.Y.; LaPierre, S.E.; Zimmer, E.L.; McNamara, D.M.; Pauly, D.F.; Sharaf, B.; Holubkov, R.; et al. Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. Circulation 2003, 107, 3146–3151.
154. Mango, R.; Clementi, F.; Borgiani, P.; Forleo, G.B.; Federici, M.; Contino, G.; Giardina, E.; Garza, L.; Fahdi, I.E.; Lauro, R.; et al. Association of single nucleotide polymorphisms in the oxidised LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. J. Med. Genet. 2003, 40, 933–936.
155. Tatsuguchi, M.; Furutani, M.; Hinagata, J.; Tanaka, T.; Furutani, Y.; Imamura, S.; Kawana, M.; Masaki, T.; Kasanuki, H.; Sawamura, T.; et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem. Biophys. Res. Commun. 2003, 28, 247–250.
156. Mango, R.; Biocca, S.; del Vecchio, F.; Clementi, F.; Sangiuolo, F.; Amati, F.; Filareto, A.; Grelli, S.; Spitalieri, P.; Filesi, I.; et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ. Res. 2005, 97, 152–158.
157. Tejedor, J.R.; Tilgner, H.; Iannone, C.; Guigó, R.; Valcárcel, J. Role of six single nucleotide polymorphisms, risk factors in coronary disease, in OLR1 alternative splicing. RNA 2015, 21, 1187–1202.
158. Karni, R.; de Stanchina, E.; Lowe, S.W.; Sinha, R.; Mu, D.; Krainer, A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 2007, 14, 185–193.
159. Das, S.; Krainer, A.R. Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer. Mol. Cancer Res. 2014, 12, 1195–1204, doi:10.1158/1541-7786.MCR-14-0131.
160. Libby, P. Inflammation in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32, 2045–2051.
161. Hansson, G.K.; Robertson, A.K.; Söderberg-Nauclér, C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 2006, 1, 297–329.
162. Pak, V.M.; Grandner, M.A.; Pack, A.I. Circulating adhesion molecules in obstructive sleep apnea and cardiovascular disease. Sleep Med. Rev. 2014, 18, 25–34.
163. Blankenberg, S.; Barbaux, S.; Tiret, L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003, 170, 191–203.
164. Osterud, B.; Bjorklid, E. Role of monocytes in atherogenesis. Physiol. Rev. 2003, 83, 1069–1112.
165. Galkina, E.; Ley, K. Immune and inflammatory mechanisms of atherosclerosis. Annu. Rev. Immunol. 2009, 27, 165–197.
166. Angelovich, T.A.; Hearps, A.C.; Jaworowski, A. Inflammation-induced foam cell formation in chronic inflammatory disease. Immunol. Cell Biol. 2015, 93, 683–693.
167. Heinecke, J.W. Lipoprotein oxidation in cardiovascular disease: Chief culprit or innocent bystander? J. Exp. Med. 2006, 203, 813–816.
168. Kataoka, H.; Kume, N.; Minami, M.; Moriwaki, H.; Sawamura, T.; Masaki, T.; Kita, T. Expression of lectin-like oxidized LDL receptor-1 in human atherosclerotic lesions. Ann. N. Y. Acad. Sci. 2000, 902, 328–335.
169. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329, 2002–2012.
170. Khaidakov, M.; Mitra, S.; Kang, B.Y.; Wang, X.; Kadlubar, S.; Novelli, G.; Raj, V.; Winters, M.; Carter, W.C.; Mehta, J.L. Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS ONE 2011, 6, e20277.
171. Baeuerle, P.A.; Henkel, T. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 1994, 12, 141–179.
172. Maziere, C.; Auclair, M.; Djavaheri-Mergny, M.; Packer, L.; Maziere, J.C. Oxidized low density lipoprotein induces activation of the transcription factor NF-κB in fibroblasts, endothelial and smooth muscle cells. IUBMB Life 1996, 39, 1201–1207.
173. Hirsch, H.A.; Iliopoulos, D.; Joshi, A.; Zhang, Y.; Jaeger, S.A.; Bulyk, M.; Tsichlis, P.N.; Liu, X.S.; Struhl, K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010, 17, 348–361.
174. Morganti, M.; Carpi, A.; Nicolini, A.; Gorini, I.; Glaviano, B.; Fini, M.; Giavaresi, G.; Mittermayer, C.; Giardino, R. Atherosclerosis and cancer: Common pathways on the vascular endothelium. Biomed. Pharmacother. 2002, 56, 317–324.
175. González-Chavarría, I.; Cerro, R.P.; Parra, N.P.; Sandoval, F.A.; Zuñiga, F.A.; Omazábal, V.A.; Lamperti, L.I.; Jiménez, S.P.; Fernandez, E.A.; Gutiérrez, N.A.; et al. Lectin-like oxidized LDL receptor-1 is an enhancer of tumor angiogenesis in human prostate cancer cells. PLoS ONE 2014, 9, e106219.
176. Murdocca, M.; Mango, R.; Pucci, S.; Biocca, S.; Testa, B.; Capuano, R.; Paolesse, R.; Sanchez, M.; Orlandi, A.; di Natale, C.; et al. The lectin-like oxidized LDL receptor-1: A new potential molecular target in colorectal cancer. Oncotarget 2016, 7, 14765–14780.
177. Jiang, L.; Jiang, S.; Lin, Y.; Yang, H.; Zhao, Z.; Xie, Z.; Lin, Y.; Long, H. Combination of body mass index and oxidized low density lipoprotein receptor 1 in prognosis prediction of patients with squamous non-small cell lung cancer. Oncotarget 2015, 6, 22072–22080.
178. Flavin, R.; Peluso, S.; Nguyen, P.L.; Loda, M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010, 6, 551–562.
179. Poynter, J.N.; Gruber, S.B.; Higgins, P.D.; Almog, R.; Bonner, J.D.; Rennert, H.S.; Low, M.; Greenson, J.K.; Rennert, G. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005, 352, 2184–2192.
180. Chan, A.O.; Jim, M.H.; Lam, K.F.; Morris, J.S.; Siu, D.C.; Tong, T.; Ng, F.H.; Wong, S.Y.; Hui, W.M.; Chan, C.K.; et al. Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007, 298, 1412–1419.
181. Qi, X.F.; Kim, D.H.; Yoon, Y.S.; Kim, S.K.; Cai, D.Q.; Teng, Y.C.; Shim, K.Y.; Lee, K.J. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol. Lett. 2010, 199, 277–287.
182. Keshavarzian, A.; Zapeda, D.; List, T.; Mobarhan, S. High levels of reactive oxygen metabolites in colon cancer tissue: Analysis by chemiluminescence probe. Nutr. Cancer 1992, 17, 243–249.
183. Otamiri, T.; Sjödahl, R. Increased lipid peroxidation in malignant tissues of patients with colorectal cancer. Cancer 1989, 64, 422–425.
184. Lu, J.; Mitra, S.; Wang, X.; Khaidakov, M.; Mehta, J.L. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid. Redox Signal. 2011, 15, 2301–2333.
185. Breslow, J.L. Cardiovascular disease burden increases, NIH funding decreases. Nat. Med. 1997, 3, 600–601.
186. Paneni, F.; Costantino, S.; Cosentino, F. Metformin and left ventricular remodeling after acute myocardial infarction: Molecular mechanisms and clinical implications. G. Ital. Cardiol. 2015, 16, 225–231.
187. Ishigaki, Y.; Katagiri, H.; Gao, J.; Yamada, T.; Imai, J.; Uno, K.; Hasegawa, Y.; Kaneko, K.; Ogihara, T.; Ishihara, H.; et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008, 118, 75–83.
188. Xu, S.; Liu, Z.; Huang, Y.; Le, K.; Tang, F.; Huang, H.; Ogura, S.; Little, P.J.; Shen, X.; Liu, P. Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation. Transl. Res. 2012, 160, 114–124.
189. Kang, B.Y.; Khan, J.A.; Ryu, S.; Shekhar, R.; Seung, K.B.; Mehta, J.L. Curcumin reduces angiotensin II-mediated cardiomyocyte growth via LOX-1 inhibition. J. Cardiovasc. Pharmacol. 2010, 55, 176–183.
190. Huang, Z.; Dong, F.; Li, S.; Chu, M.; Zhou, H.; Lu, Z.; Huang, W. Berberine-induced inhibition of adipocyte enhancer-binding protein 1 attenuates oxidized low-density lipoprotein accumulation and foam cell formation in phorbol 12-myristate 13-acetate-induced macrophages. Eur. J. Pharmacol. 2012, 690, 164–169.
191. Chang, H.C.; Chen, T.G.; Tai, Y.T.; Chen, T.L.; Chiu, W.T.; Chen, R.M. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J. Cereb. Blood Flow Metab. 2011, 31, 842–854.
192. Sugano, M.; Tsuchida, K.; Makino, N. Nifedipine prevents apoptosis of endothelial cells induced by oxidized low-density lipoproteins. J. Cardiovasc. Pharmacol. 2002, 40, 146–152.
193. Mehta, J.L.; Sanada, N.; Hu, C.P.; Chen, J.; Dandapat, A.; Sugawara, F.; Satoh, H.; Inoue, K.; Kawase, Y.; Jishage, K.; et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 2007, 100, 1634–1642.
194. Ishino, S.; Mukai, T.; Kume, N.; Asano, D.; Ogawa, M.; Kuge, Y.; Minami, M.; Kita, T.; Shiomi, M.; Saji, H. Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability analysis in hypercholesterolemic rabbits. Atherosclerosis 2007, 195, 48–56.
195. Li, D.; Williams, V.; Liu, L.; Chen, H.; Sawamura, T.; Antakli, T.; Mehta, J.L. LOX-1 inhibition in myocardial ischemia-reperfusion injury: Modulation of MMP-1 and inflammation. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H1795–H1801.
196. Li, D.; Liu, L.; Chen, H.; Sawamura, T.; Ranganathan, S.; Mehta, J.L. LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 2003, 107, 612–617.
197. Lin, L.; Gong, H.; Zhou, N.; Jiang, G.; Wu, J.; Li, L. Oxidized Low-Density Lipoprotein-Induced Cardiac Hypertrophy is Partly Mediated by Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Activating Angiotensin II Type 1 Receptor Independent of Angiotensin II; World Congress of Cardiology Scientific Sessions: Beijing, China, 2010.
198. Nakano, A.; Inoue, N.; Sato, Y.; Nishimichi, N.; Takikawa, K.; Fujita, Y.; Kakino, A.; Otsui, K.; Yamaguchi, S.; Matsuda, H.; et al. LOX-1 mediates vascular lipid retention under hypertensive state. J. Hypertens. 2010, 28, 1273–1280.
199. Lund, A.K.; Lucero, J.; Harman, M.; Madden, M.C.; McDonald, J.D.; Seagrave, J.C.; Campen, M.J. The oxidized low-density lipoprotein receptor mediates vascular effects of inhaled vehicle emissions. Am. J. Respir. Crit. Care Med. 2011, 184, 82–91.
200. Ishino, S.; Mukai, T.; Kuge, Y.; Kume, N.; Ogawa, M., Takai, N.; Kamihashi, J.; Shiomi, M.; Minami, M.; Kita, T.; et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: Potential agent for imaging of vulnerable plaque. J. Nucl. Med. 2008, 49, 1677–1685.
201. O’Connor, T.P.; Crystal, R.G. Genetic medicines: Treatment strategies for hereditary disorders. Nat. Rev. Genet. 2006, 7, 261–276.
202. Lee, R.G.; Crosby, J.; Baker, B.F.; Graham, M.J.; Crooke, R.M. Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics. J. Cardiovasc. Transl. Res. 2013, 6, 969–980.
203. Li, Y.; Chi, L.; Stechschulte, D.J.; Dileepan, K.N. Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-α. Microvasc. Res. 2001, 61, 253–262.
204. Amati, F.; Diano, L.; Vecchione, L.; Norata, G.D.; Koyama, Y.; Cutuli, L.; Catapano, A.L.; Romeo, F.; Ando, H.; Novelli, G. LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. Mol. Ther. Nucleic Acids 2012, 1, e58, doi:10.1038/mtna.2012.45.
205. Hua, Y.; Vickers, T.A.; Okunola, H.L.; Bennett, C.F.; Krainer, A.R. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet. 2008, 82, 834–848.
206. Kole, R.; Krainer, A.R.; Altman, S. RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 2012, 11, 125–140.
207. Bechara, E.G.; Sebestyén, E.; Bernardis, I.; Eyras, E.; Valcárcel, J. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 2013, 52, 720–733.
208. Maimon, A.; Mogilevsky, M.; Shilo, A.; Golan-Gerstl, R.; Obiedat, A.; Ben-Hur, V.; Lebenthal-Loinger, I.; Stein, I.; Reich, R.; Beenstock, J.; et al. Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation. Cell Rep. 2014, 7, 501–513.
209. Ambros, V. The functions of animal microRNAs. Nature 2004, 431, 350–355.
210. Krol, J.; Loedige, I.; Filipowicz, W. The wide spread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11, 597–610.
211. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233.
212. Guo, H.; Ingolia, N.T.; Weissman, J.S.; Bartel, D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466, 835–840.
213. Valencia-Sanchez, M.A.; Liu, J.; Hannon, G.J.; Parker, R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006, 20, 515–524.
214. Baek, D.; Villén, J.; Shin, C.; Camargo, F.D.; Gygi, S.P.; Bartel, D.P. The impact of microRNAs on protein output. Nature 2008, 455, 64–71.
215. Chen, K.C.; Hsieh, I.C.; His, E.; Wang, Y.S.; Dai, C.Y.; Chou, W.W.; Juo, S.H. Negative feedback regulation between microRNA let-7g and the oxLDL receptor LOX-1. J. Cell Sci. 2011, 124, 4115–4124.
216. Ding, Z.; Wang, X.; Khaidakov, M.; Liu, S.; Mehta, J.L. MicroRNA hsa-let-7g targets lectin-like oxidized low-density lipoprotein receptor-1 expression and inhibits apoptosis in human smooth muscle cells. Exp. Biol. Med. 2012, 237, 1093–1100.
217. Dai, Y.; Zhang, Z.; Cao, Y.; Mehta, J.L.; Li, J. MiR-590-5p Inhibits Oxidized- LDL Induced Angiogenesis by Targeting LOX-1. Sci. Rep. 2016, 6, 22607, doi:10.1038/srep22607.
218. Luo, P.; Zhang, W.F.; Qian, Z.X.; Zhang, Z. MiR-590-5p-mediated LOX-1 upregulation promotes Angiotensin II-induced endothelial cell apoptosis. Biochem. Biophys. Res. Commun. 2016, 471, 402–408.
219. Morini, E.; Rizzacasa, B.; Pucci, S.; Polidoro, C.; Ferrè, F.; Caporossi, D.; Helmer Citterich, M.; Novelli, G.; Amati, F. The human rs1050286 polymorphism alters LOX-1 expression through modifying miR-24 binding. J. Cell. Mol. Med. 2016, 20, 181–187.
220. Guo, X.; Xiang, Y.; Yang, H.; Yu, L.; Peng, X.; Guo, R. Association of the LOX-1 rs1050283 Polymorphism with Risk for Atherosclerotic Cerebral Infarction and its Effect on sLOX-1 and LOX-1 Expression in a Chinese Population. J. Atheroscler. Thromb. 2016, doi:10.5551/jat.36327.
221. Sugimoto, K.; Ishibashi, T.; Sawamura, T.; Inoue, N.; Kamioka, M.; Uekita, H.; Ohkawara, H.; Sakamoto, T.; Sakamoto, N.; Okamoto, Y.; et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc. Res. 2009, 84, 127–136.
222. Fujita, Y.; Kakino, A.; Nishimichi, N.; Yamaguchi, S.; Sato, Y.; Machida, S.; Cominacini, L.; Delneste, Y.; Matsuda, H.; Sawamura, T. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin. Chem. 2009, 55, 285–924.
223. Lu, J.; Yang, J.H.; Burns, A.R.; Chen, H.H.; Tang, D.; Walterscheid, J.P.; Suzuki, S.; Yang, C.Y.; Sawamura, T.; Chen, C.H. Mediation of electronegative low-density lipoprotein signaling by LOX-1: A possible mechanism of endothelial apoptosis. Circ. Res. 2009, 104, 619–627.
224. Nishizuka, T.; Fujita, Y.; Sato, Y.; Nakano, A.; Kakino, A.; Ohshima, S.; Kanda, T.; Yoshimoto, R.; Sawamura, T. Procyanidins are potent inhibitors of LOX-1: A new player in the French Paradox. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2011, 87, 104–113.
225. Hung, C.H.; Chan, S.H.; Chu, P.M.; Lin, H.C.; Tsai, K.L. Metformin regulates oxLDL-facilitated endothelial dysfunction by modulation of SIRT1 through repressing LOX-1-modulated oxidative signaling. Oncotarget 2016, 7, 10773–10787.
226. Biocca, S.; Iacovelli, F.; Matarazzo, S.; Vindigni, G.; Oteri, F.; Desideri, A.; Falconi, M. Molecular mechanism of statin-mediated LOX-1 inhibition. Cell Cycle 2015, 14, 1583–1595.